Malarial researcher J. Alexandra Rowe of the University of Edinburgh presented top-line preclinical data for Immunovaccine's (OTCQX:IMMVF; TSX:IMV) DepoVax-based malarial vaccine at the World Vaccine Congress Europe in Barcelona, Spain.
Results from studies in mice, conducted in collaboration with the university’s Centre for Immunity, Infection and Evolution (CIIE), indicated that the novel CIIE-identified targets, when formulated in the DepoVax targeting platform, generated strong, sustained, antibody responses that could prevent, after a single injection, a process in severe malaria known as rosetting.
"DepoVax is emerging as an ideal enabling agent for novel treatments being developed to address some of the world's most challenging infectious diseases, including malaria," Marianne Stanford, Immunovaccine's VP of research, said in a statement.
"Severe malaria continues to present a significant worldwide health concern, and we believe that a vaccine that can address its most virulent forms, in particular the rosetting process, could positively impact global malaria-related mortality rates,” she added.
Data showed that the resulting vaccine candidate formulated in the DepoVax platform could generate antibodies that prevented the rosetting process. In addition, researchers were able to combine antigens into a single vaccine administration that was able to protect red blood cells from rosetting across a wide range of malarial strains.
Immunovaccine is looking to continue development efforts in this disease area, via collaborations with the University of Edinburgh and Leidos/USAID.